Daraxonrasib trial shrinks pancreatic tumors; undetectable in 1 in 12 patients
Published 1 d ago2 sourcesEvidence: Reported
A phase trial of a once-daily oral drug combined with chemotherapy reportedly eliminated disease in roughly 1 in 12 patients with advanced pancreatic cancer, per RTÉ. The result is early-stage and unverified; durability and survival benefit remain unquantified. If confirmed, it would mark a meaningful advance in a malignancy with historically poor outcomes.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Published 1 d ago2 sourcesEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 16 h ago1 sourceEvidence: Reported
Published 3 d ago1 sourceEvidence: Reported
Published 1 d ago2 sourcesEvidence: Reported
Published 12 h ago1 sourceEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported